Immunotherapy Delivery Preference for Kidney Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is to see if people prefer immunotherapy treatment for kidney cancer delivered intravenously or subcutaneously and if it is practical for participants to receive labs at home and have a video (telehealth) visit with their doctor prior to their day of treatment.
Who Is on the Research Team?
Sahil Doshi, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Are You a Good Fit for This Trial?
This trial is for people diagnosed with kidney cancer who are eligible to receive immunotherapy. Participants should be able to try different ways of getting their treatment and may need access to telehealth and home lab services.Inclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Nivolumab
- Pembrolizumab
Trial Overview
The study compares two ways of giving immunotherapy drugs (nivolumab or pembrolizumab) for kidney cancer: through a vein (IV) or under the skin (subcutaneous). It also looks at whether home lab tests and video doctor visits work well before treatment.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Participants will be randomized to receive subcutaneous nivolumab/NIVO or pembrolizumab/PEMBRO
Participants will be randomized to receive IV nivolumab/NIVO or pembrolizumab/PEMBRO
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.